Skip to main content

Jerel Davis's Form 4 filing

Repare Therapeutics Inc.RPTX · filed Jun 7, 2022

Accession no.
0000899243-22-021345
Filed
Jun 7, 2022
Trade date
Jun 3-6, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 17 non-derivative transactions. Open-market sales total $9.19M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Jerel DavisCIK 0001745958Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 3, 2022Common SharesSSaleDisposed−250,000$12.25F1−$3,062,5002,344,451Indirect
Jun 3, 2022Common SharesSSaleDisposed−438,795$12.25F1−$5,375,238.751,464,875Indirect
Jun 3, 2022Common SharesSSaleDisposed−13,199$12.25F1−$161,687.7544,065Indirect
Jun 3, 2022Common SharesSSaleDisposed−14,611$12.25F1−$178,984.7548,776Indirect
Jun 3, 2022Common SharesSSaleDisposed−33,395$12.25F1−$409,088.75111,484Indirect
Jun 6, 2022Common SharesJOtherDisposed−614,315$0.00$0850,560Indirect
Jun 6, 2022Common SharesJOtherAcquired+132,692$0.00$0132,692Indirect
Jun 6, 2022Common SharesJOtherDisposed−18,478$0.00$025,587Indirect
Jun 6, 2022Common SharesJOtherAcquired+3,992$0.00$0136,684Indirect
Jun 6, 2022Common SharesJOtherDisposed−20,454$0.00$028,322Indirect
Jun 6, 2022Common SharesJOtherAcquired+4,419$0.00$0141,103Indirect
Jun 6, 2022Common SharesJOtherDisposed−141,103$0.00$00Indirect
Jun 6, 2022Common SharesJOtherAcquired+2,653$0.00$014,429Direct
Jun 6, 2022Common SharesJOtherDisposed−46,753$0.00$064,731Indirect
Jun 6, 2022Common SharesJOtherAcquired+10,099$0.00$010,099Indirect
Jun 6, 2022Common SharesJOtherDisposed−10,099$0.00$00Indirect
Jun 6, 2022Common SharesJOtherAcquired+6,448$0.00$020,877Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Referenced by the price of 5 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)